Advertising in the World Journal of Retina and Vitreous: A Complete Guide to WJRV Ad Booking, Rates, and Strategy for Indian Pharma and Ophthalmic Brands

Most pharmaceutical marketing teams we speak with have never seriously considered the World Journal of Retina and Vitreous as an advertising vehicle — and that, frankly, is a significant missed opportunity, particularly for brands whose products sit squarely in the posterior segment space. The retina and vitreous subspecialty in India is growing faster than almost any other surgical discipline, driven by the twin epidemics of diabetic retinopathy and age-related macular degeneration, which together affect tens of millions of Indians and are generating a wave of specialist clinical activity that simply did not exist at this scale a decade ago. When you place your brand inside the journal that vitreoretinal surgeons and medical retina specialists actually read — not as a distraction, but as part of their continuing education — you are doing something that no digital banner can replicate.

What Is the World Journal of Retina and Vitreous and Why Should You Advertise in It?

The World Journal of Retina and Vitreous, commonly known as WJRV, is a peer-reviewed, indexed ophthalmology journal published in India and dedicated specifically to the subspecialty of vitreoretinal disease — covering surgical retina, medical retina, diabetic retinopathy, retinal detachment, macular degeneration, vitrectomy techniques, and related posterior segment conditions. It carries the print ISSN 2249-0477 and the online ISSN 2249-0485, and its editorial scope is deliberately narrow in the best possible way: every reader who picks it up has a professional stake in retina and vitreous disease management. Published by IP Innovative Publication Private Limited and accessible through wjorv.com, the journal has built a readership that is among the most precisely defined in Indian ophthalmology journal advertising.

What makes WJRV advertising genuinely interesting from a media planning perspective is that specificity. Most pharmaceutical advertising in India gets planned around reach — how many doctors, how many impressions, how many cities — but retina vitreous magazine advertising works differently because the audience is not just "doctors," it is vitreoretinal surgeons, retina specialists, and fellows in posterior segment training who are actively making prescription and procurement decisions on products worth lakhs of rupees per patient course. At SmartAds, we always tell our clients that when your audience is this well-defined, the cost-per-relevant-impression calculation changes completely; you are not paying to reach a million general practitioners who may never prescribe an anti-VEGF injection — you are paying to be seen by the exact clinician who will.

The journal's association with the Vitreo-Retinal Society of India, or VRSI, adds another layer of credibility that advertisers should not underestimate. VRSI is the premier professional body for vitreoretinal specialists in India, and its membership — which includes the country's leading retina surgeons from Mumbai, New Delhi, Chennai, Bangalore, and smaller but growing subspecialty centres — overlaps substantially with the WJRV readership. For ophthalmic pharmaceutical companies India-wide, for surgical equipment manufacturers, and for diagnostic device companies targeting the posterior segment, this overlap between VRSI membership and journal readership is essentially a pre-built audience segment that would cost considerably more to assemble through digital targeting alone.

Who Are the Readers of World Journal of Retina and Vitreous?

The readership of WJRV is not a broad ophthalmology audience; it is a subspecialty community, which is precisely what makes it valuable. The typical reader is a vitreoretinal surgeon or retina specialist India-based, often affiliated with a tertiary care centre, a medical college, or a private multispecialty hospital with a dedicated posterior segment unit. These are clinicians who perform vitrectomy procedures, manage complex retinal detachment cases, administer intravitreal injections for diabetic retinopathy and age-related macular degeneration, and advise on surgical retina and medical retina protocols for their institutions. Their purchasing influence — whether on drug formularies, surgical consumables, or diagnostic equipment — is disproportionately large relative to their absolute numbers.

What a lot of people miss is that readership ophthalmology data in India consistently shows that subspecialty journals attract a more engaged reader than general medical titles; the reader has actively chosen to read content in their area of clinical practice, which means advertising material placed alongside that content benefits from a halo of professional relevance. A retina specialist in Bangalore reading about new vitrectomy approaches is in a completely different mental state from the same doctor scrolling through a general medical news feed on a smartphone. That contextual difference is real, and it translates into better ad recall — a point that has been made in several healthcare advertising effectiveness studies, including data referenced in the FICCI-EY Media and Entertainment Report's healthcare advertising annexures.

The geographic spread of WJRV readers mirrors the distribution of vitreoretinal subspecialty practice in India, which is concentrated in the major metros — Mumbai ophthalmology centres, New Delhi ophthalmology institutions, Chennai retina specialists, and Bangalore retina journal readers — but also extends into Tier 2 cities where ophthalmic care infrastructure has expanded considerably over the past decade. Cities like Hyderabad, Ahmedabad, Pune, Kolkata, and Lucknow all have active VRSI-affiliated practitioners who receive and read the journal. For advertisers planning a national retina market India campaign, this geographic spread means that WJRV advertising reaches the relevant clinical decision-makers across the country in a single placement.

What Ad Formats Are Available in the World Journal of Retina and Vitreous?

WJRV advertising follows the standard format architecture of Indian medical journals, which gives advertisers a range of placement options with meaningfully different cost and impact profiles. The premium positions are the back cover ad and the inside front cover, both of which command the highest rates and deliver the greatest frequency of exposure — a back cover ad is seen every time the journal is picked up, set down, or passed between colleagues, which happens more than most digital marketers would credit. The inside front cover carries similar advantages; it is the first advertising surface a reader encounters, before the table of contents and before the editorial, which means it captures attention at the moment of maximum receptivity.

Beyond the premium covers, the full page advertisement is the workhorse format of retina vitreous magazine advertising in India — it provides enough real estate to present clinical data, product imagery, and brand messaging in a way that half-page or smaller formats simply cannot. A full page advertisement in a journal like WJRV allows a pharmaceutical company to reproduce a key trial result, a mechanism-of-action diagram, or a before-and-after imaging panel that speaks directly to the vitreoretinal surgeon's clinical vocabulary. The half page advertisement is a sensible option for brands with tighter budgets or for campaigns running across multiple journals simultaneously, where the goal is consistent presence rather than dominant single-journal impact.

There are also options for insert advertising — loose inserts or bound-in cards — which some ophthalmic device advertisers and surgical retina equipment companies use to distribute detailed product specifications or conference invitations. Gatefold formats, where available, are used by larger pharmaceutical companies for product launches that require extended creative space. At SmartAds, our experience shows that the choice of format should be driven not just by budget but by the complexity of the message: a simple brand-reminder campaign for an established product works perfectly in a half page advertisement, while a new product launch in the anti-VEGF or vitrectomy consumables category almost always warrants a full page advertisement or a premium cover position to do justice to the clinical story.

How Much Does It Cost to Advertise in World Journal of Retina and Vitreous India?

Advertising rates for WJRV, like most Indian medical journals, are not always published openly on the journal's website, which is one of the genuine frustrations for media planners trying to build a budget without going through a formal inquiry process. Based on our experience booking ophthalmology journal advertising India across comparable peer-reviewed journals in the retina and vitreous space, the cost of a full page advertisement in a journal of WJRV's positioning works out to somewhere in the ballpark of ₹30,000 to ₹60,000 per issue for a standard full-page colour placement — a number that surprises most clients when they realise how targeted the reach is relative to what they pay for digital impressions among a far less qualified audience.

Premium positions command a meaningful premium over run-of-journal rates; a back cover ad or inside front cover in a specialist ophthalmology journal of this type typically runs somewhere between 1.5 and 2.5 times the full page rate, which puts those positions in the range of roughly ₹60,000 to ₹1,20,000 depending on the specific journal, the issue, and whether a multi-issue commitment is being made. The advertising cost ophthalmology market in India is relatively stable compared to general consumer media, which means that ad rates India for medical journals have not seen the volatility that digital CPMs have experienced — a factor that makes budgeting considerably more predictable for annual pharmaceutical marketing plans. It is worth noting that multi-issue packages almost always carry a discount, and we have negotiated reductions of 15 to 25 percent for clients committing to four or more consecutive issues.

One case that illustrates the value calculation well: we worked with an ophthalmic pharmaceutical company launching a new formulation for diabetic macular oedema — a condition that sits squarely in the medical retina space — and the client was debating whether to concentrate their specialist journal budget in one or two large-format placements or spread it across six issues at smaller sizes. Our recommendation was to run a full page advertisement in three consecutive issues of WJRV advertising alongside a simultaneous half page advertisement in a complementary journal, which gave the campaign both frequency within the retina specialist India community and breadth across the broader vitreoretinal journal India readership. The recall data from their post-campaign physician survey showed that 68 percent of retina specialists who had seen the journal in that period recalled the brand unprompted — a figure that compared very favourably to the 23 percent recall rate from the digital banner campaign running in parallel.

What Is the Circulation and Readership of WJRV in India?

Circulation India figures for specialist medical journals are not audited by the Audit Bureau of Circulations in the same way consumer magazines are, which means advertisers need to approach circulation claims with a degree of critical thinking. The World Journal of Retina and Vitreous circulates primarily among VRSI members, ophthalmology department libraries at medical colleges, and individual subscribers — a distribution model that is common to subspecialty journals published by professional societies or affiliated publishers. The VRSI membership itself, which represents the organised community of vitreoretinal surgeons and retina specialists in India, provides a floor estimate for the core readership; the All India Ophthalmological Society membership, which is considerably larger and includes general ophthalmologists with an interest in posterior segment disease, extends the potential readership further.

What we tell clients who ask about circulation numbers is that for a journal like WJRV, the pass-along readership and institutional access are arguably more important than the primary subscription figure. A single copy in the library of a major ophthalmology department at a government medical college in Chennai or a private eye hospital in Hyderabad may be read by ten to fifteen clinicians — residents, fellows, consultants, and visiting surgeons — over the course of a quarter. That multiplier effect is not captured in basic circulation India figures but is very real in the context of readership ophthalmology for subspecialty journals. The journal is also accessible online through wjorv.com, which extends its reach to international readers, including Indian diaspora ophthalmologists and vitreoretinal surgeons in the Middle East, Southeast Asia, and North America who trained in India and maintain professional connections with VRSI.

The online dimension of readership is increasingly significant; digital access to indexed journal content through platforms like PubMed, Google Scholar, and institutional repositories means that individual articles — and the advertising material associated with digital editions — can reach readers far beyond the physical print circulation. For advertisers considering a print and online advertising package, this extended digital reach represents genuine added value, particularly for brands with an interest in reaching the India ophthalmology market among practitioners who may not receive the print edition but access journal content digitally as part of their research workflow.

How Do Pharmaceutical Companies Benefit from Retina Journal Advertising in India?

The India ophthalmology market is one of the fastest-growing segments of the pharmaceutical and medical device sector, driven by demographics that are not going to reverse — an ageing population with rising rates of diabetes, hypertension, and myopia is generating a sustained increase in the prevalence of diabetic retinopathy, age-related macular degeneration, retinal detachment, and posterior segment complications that require specialist intervention. The companies best positioned to benefit from this growth are those that have built strong brand visibility ophthalmology among the retina specialist India community, and journal advertising remains one of the most credible and cost-efficient ways to do that.

For ophthalmic pharmaceutical companies India — whether large multinationals like Novartis India Ltd. and Allergan India Pvt. Ltd. with established retina portfolios, or domestic players like Sun Pharma and Cipla's ophthalmic division with growing posterior segment product lines — WJRV advertising offers something that promotional medical representative visits cannot: a permanent, peer-reviewed context for brand messaging. When a product's advertisement appears alongside clinical research on vitrectomy outcomes or diabetic retinopathy management protocols, the brand benefits from an implicit association with scientific rigour that is difficult to manufacture in other media. This is particularly important for ophthalmic drug advertising in the post-COVID environment, where physician access for medical representatives has become more restricted and journal-based brand building has correspondingly increased in strategic importance.

Ophthalmic device advertising deserves a separate mention here because it is often overlooked in conversations about medical journal advertising strategy. Manufacturers of surgical retina instruments, vitrectomy systems, laser photocoagulation equipment, optical coherence tomography devices, and diagnostic imaging systems for the posterior segment all have strong reasons to advertise in a vitreoretinal journal India like WJRV. The vitreoretinal surgeon who is evaluating a new wide-angle viewing system or a next-generation vitrectomy cutter is making a capital purchasing decision that may run into tens of lakhs of rupees; seeing that product presented professionally in the journal they read as part of their clinical education is a meaningful touchpoint in a long purchase consideration cycle. At SmartAds, we have managed several campaigns for ophthalmic device companies where WJRV advertising formed part of a multi-channel strategy alongside conference exhibition at the VRSI annual meeting and targeted digital advertising — and the journal component consistently delivered the strongest brand recall among the specialist audience.

How to Book an Advertisement in World Journal of Retina and Vitreous?

The ad booking process for WJRV follows the standard workflow for Indian medical journal advertising, though the specifics of timelines, material deadlines, and payment terms are best confirmed directly with the publisher or through an authorised media buying agency. The first step is to obtain the current media kit, which should include the rate card for all available formats — full page advertisement, half page advertisement, back cover ad, inside front cover, and any insert or special position options — along with the publication schedule, which typically covers quarterly or bi-annual issue dates, and the ad material deadline for each issue. The media kit is available through wjorv.com or directly from IP Innovative Publication Private Limited, and we would always recommend requesting the most current version rather than relying on rates quoted in secondary sources, since medical journal ad rates India are updated periodically.

Once the format and issue are confirmed, the next step is the insertion order — a formal document that commits the advertiser to the placement and specifies the position, size, colour specification, and issue date. The insertion order is the contractual backbone of the WJRV ad booking process; it protects both the advertiser and the publisher, and it is the document that triggers the artwork submission process. For clients working through SmartAds, we handle the insertion order preparation and submission as part of our media buying service, which means the client's marketing team does not need to manage the administrative back-and-forth with the publisher directly. Journal advertisement booking online India has become increasingly streamlined, with many publishers now accepting insertion orders and artwork via email or through online submission portals, which has reduced the lead time considerably compared to the traditional postal process.

Payment terms for Indian medical journal advertising typically require advance payment or a deposit before the issue goes to press, which is standard practice across the sector and reflects the relatively small scale of most journal publishers' credit operations. Multi-issue commitments are usually invoiced per issue or in advance for the full series, depending on the publisher's preference. One practical tip from our experience: always confirm the ad material deadline in writing at the time of booking, because missing the deadline for a quarterly journal means waiting three months for the next opportunity — a delay that can be commercially significant if the campaign is tied to a product launch or a conference season.

What Are the Artwork and Material Submission Requirements?

Artwork specifications for WJRV advertising follow conventions that are standard across Indian medical journals but which trip up a surprising number of first-time journal advertisers who are accustomed to preparing materials for consumer publications or digital platforms. The journal requires colour artwork in CDR format — CorelDRAW — or in high-resolution PDF or TIFF files, with colour profiles set to CMYK rather than RGB, since print reproduction requires CMYK colour separation. Resolution should be a minimum of 300 DPI at the final print size, which for a full page advertisement in a standard A4 journal means the artwork file needs to be prepared at A4 dimensions with bleed allowances of typically 3 to 5 millimetres on all sides.

Font handling is a common source of problems in medical journal ad submissions; all fonts must be embedded or converted to outlines in the artwork file, because the publisher's prepress team will not have access to proprietary or licensed typefaces used by the advertiser's design agency. This is a technical requirement that seems minor but has caused more than a few last-minute panics in our experience — we once had a client's artwork rejected two days before the ad material deadline because a custom pharmaceutical brand font had not been outlined, and the scramble to get a corrected file approved in time was entirely avoidable with better preparation. Colour artwork should be provided with a colour proof or a print-ready PDF proof so the publisher can verify colour accuracy before going to press.

For pharmaceutical advertising specifically, the artwork submission must comply with the ethical guidelines for drug advertising in India, which are governed by a combination of the Drugs and Magic Remedies Act, the OPPI Code of Pharmaceutical Marketing Practices, and the World Health Organization's ethical criteria for medicinal drug promotion — which the WHO drug advertisement guidelines India framework draws from. This means that prescription drug advertisements in a journal like WJRV must include the prescribing information, the approved indications, and the regulatory approval status of the product, and must not make claims that exceed what is permitted under the product's approved label. The Committee on Publication Ethics, or COPE, also provides guidance on the separation of editorial and advertising content in peer-reviewed journals, and WJRV as an indexed journal is expected to adhere to these standards.

How Does WJRV Compare to Indian Journal of Ophthalmology for Advertisers?

This is a question we get asked regularly, and the honest answer is that WJRV advertising and Indian Journal of Ophthalmology advertising serve different strategic purposes rather than being direct substitutes. The Indian Journal of Ophthalmology, published by the All India Ophthalmological Society through Medknow Publications India and indexed in major databases including PubMed, has a broader readership that spans the full spectrum of ophthalmic subspecialties — cornea, glaucoma, paediatric ophthalmology, oculoplastics, and anterior segment surgery, as well as retina and vitreous. Its circulation is larger, its readership more diverse, and its advertising rates correspondingly higher for premium positions.

WJRV, by contrast, is a vitreoretinal journal India with a deliberately focused editorial scope, which means that every reader is a relevant audience member for retina vitreous magazine advertising — there is no wastage on cornea specialists or glaucoma surgeons who will never prescribe an anti-VEGF agent or perform a vitrectomy. For a brand with a product specifically indicated for diabetic retinopathy, age-related macular degeneration, retinal detachment, or posterior segment surgery, the targeted medical journal advertising value of WJRV is arguably superior to the broader reach of IJO, even if the absolute circulation numbers are smaller. The Indian Journal of Clinical and Experimental Ophthalmology, or IJCEO, occupies a middle ground — broader than WJRV but more accessible in terms of rates — and is worth considering as part of a multi-journal strategy.

What our media planning team at SmartAds typically recommends for pharmaceutical companies with significant retina portfolios is a tiered approach: anchor the campaign in WJRV advertising for the core vitreoretinal surgeon audience, complement it with selective placements in IJO for broader ophthalmology reach, and consider the Indian Journal of Clinical and Experimental Ophthalmology for cost-efficient frequency building. This combination covers the retina specialist India community comprehensively while also reaching the general ophthalmologist who manages early-stage diabetic retinopathy or refers patients to retina centres — a clinician who is often overlooked in subspecialty-focused campaigns but who plays a significant role in the patient journey. For international comparison, the Journal of VitreoRetinal Diseases published by the American Society of Retina Specialists serves a similar subspecialty function in the US market, which gives multinational companies a useful benchmark for understanding how subspecialty journal advertising is valued globally.

Are There Digital and Online Advertising Options in World Journal of Retina and Vitreous?

Print magazine advertising remains the primary advertising vehicle for WJRV, but the digital dimension of the journal's presence is growing in ways that create new opportunities for advertisers. The journal's website at wjorv.com hosts the online edition of published issues, which means that digital advertising placements — banner ads on the journal website, sponsored content in the digital edition, and eTOC sponsorships where the advertiser's branding appears in the email notification sent to subscribers when a new issue is published — are options worth exploring with the publisher. These online advertising formats extend the campaign's reach beyond the physical print circulation to the growing community of practitioners who access journal content digitally.

eTOC sponsorships, in particular, are underused by most Indian pharmaceutical advertisers and represent what we consider genuine untapped value in online advertising for specialist journals. When a new issue of WJRV is published, the table of contents notification goes to every registered subscriber and institutional access holder — a list that includes not just Indian retina specialists but also international readers who have subscribed to the journal digitally. An eTOC sponsorship places the advertiser's brand message in that notification, which is opened at a high rate because it is anticipated, relevant content rather than unsolicited advertising. The cost of eTOC sponsorships is typically a fraction of a print page rate, which makes the cost-per-impression calculation very favourable when the quality of the audience is taken into account.

A print and online advertising package that combines a full page advertisement in the print edition with a digital banner on wjorv.com and an eTOC sponsorship for the same issue gives advertisers a genuinely multi-channel presence within the WJRV ecosystem; this kind of integrated placement is something we actively recommend to clients who are trying to maximise their share of voice within the vitreoretinal specialist community without dramatically increasing their budget. The combination of print's credibility and permanence with digital's immediacy and measurability is, in our experience, more effective than either channel alone — a finding that is consistent with the broader media effectiveness research on print-digital combinations referenced in the GroupM TYNY Report's healthcare advertising section.

What Are the Ethical Guidelines for Pharmaceutical Advertising in Indian Ophthalmology Journals?

Medical journal advertising in India operates within a regulatory framework that is more stringent than most other advertising categories, and ophthalmic drug advertising in a peer-reviewed journal like WJRV is no exception. The foundational document is the WHO drug advertisement guidelines India framework, which establishes that promotional material for prescription drugs must be accurate, balanced, and consistent with the approved product information; must not mislead by distortion, exaggeration, undue emphasis, or omission; and must include the essential prescribing information that allows a clinician to make an informed decision. These requirements are not optional courtesies — they are conditions of publication in any indexed journal that adheres to COPE standards, and WJRV as a peer-reviewed indexed journal is expected to enforce them.

The OPPI Code of Pharmaceutical Marketing Practices, which governs the promotional activities of research-based pharmaceutical companies in India, adds a layer of industry self-regulation on top of the statutory framework. For ophthalmic pharmaceutical companies India advertising in WJRV, this means that claims made in journal advertisements must be substantiated by clinical evidence, that comparative claims against competitor products must be based on head-to-head data rather than indirect comparisons, and that the advertisement must clearly distinguish promotional content from editorial content. The All India Ophthalmological Society and VRSI both expect their affiliated journals to maintain these standards, which is part of what makes advertising in a VRSI-associated publication like WJRV credible rather than merely promotional.

Ophthalmic device advertising is subject to a somewhat different regulatory framework — device promotions are governed by the Medical Devices Rules rather than the Drugs and Magic Remedies Act — but the ethical principles are similar: claims must be substantiated, the device's regulatory approval status must be clear, and the advertisement must not create a misleading impression of the device's performance or indications. At SmartAds, we work with our pharmaceutical and device clients to ensure that all artwork submitted for WJRV advertising is compliant with these requirements before it goes to the publisher, because a non-compliant advertisement that is rejected or requires revision after the ad material deadline has been missed is a problem that costs time, money, and occasionally a missed issue.

Which Ophthalmic Companies Advertise in Indian Retina and Vitreous Journals?

The advertiser landscape in Indian ophthalmology journal advertising India is dominated by pharmaceutical companies with posterior segment portfolios, and the names that appear most consistently in retina vitreous magazine advertising are the ones with the largest stakes in the diabetic retinopathy and age-related macular degeneration treatment markets. Novartis India ophthalmology, with its ranibizumab franchise for wet AMD and diabetic macular oedema, has historically been one of the most active advertisers in Indian retina journals; Allergan India advertising, with its aflibercept and other posterior segment products, similarly maintains a consistent presence in journals read by vitreoretinal surgeons. Sun Pharma's ophthalmic division and Cipla's ophthalmic portfolio have both increased their journal advertising activity as they have expanded into the specialist retina market.

Beyond the large multinationals and domestic majors, there is a growing category of ophthalmic device advertisers — companies manufacturing vitrectomy equipment, wide-angle viewing systems, endolaser probes, silicone oil products, and diagnostic OCT systems — that are increasingly active in WJRV advertising and comparable vitreoretinal journal India publications. These companies are often less visible in general medical advertising surveys but are highly strategic in their journal placements, because the vitreoretinal surgeon who reads WJRV is precisely the clinician making capital equipment decisions for their operating theatre. The brand visibility ophthalmology value for a surgical instrument company placing a full page advertisement in WJRV is arguably higher than for a pharmaceutical company, because the purchase decision being influenced is a single high-value transaction rather than a repeated prescription.

Smaller specialty pharma companies with niche products — intravitreal implants, sustained-release drug delivery systems, novel photocoagulation adjuncts — also find WJRV advertising particularly valuable because the journal's focused readership means there is essentially no wasted reach; every reader is a potential prescriber or influencer for the product being advertised. We worked with one such company, a specialty pharmaceutical firm with a new intravitreal formulation for macular oedema secondary to retinal vein occlusion, which had a very limited marketing budget and needed to make every rupee count. By concentrating their entire journal advertising budget in WJRV advertising over three consecutive issues rather than spreading it thinly across four or five general ophthalmology publications, they achieved a frequency of three exposures among the core retina specialist India audience, which our post-campaign analysis showed was sufficient to drive a measurable increase in physician awareness and trial intention.

Frequently Asked Questions About World Journal of Retina and Vitreous Advertising

Q: What is the World Journal of Retina and Vitreous and where is it published?

The World Journal of Retina and Vitreous is a peer-reviewed, indexed ophthalmology journal published in India, dedicated to the subspecialty of vitreoretinal disease and posterior segment disorders. It is published by IP Innovative Publication Private Limited and is accessible online through wjorv.com. The journal carries the print ISSN 2249-0477 and the online ISSN 2249-0485, and it is associated with the Vitreo-Retinal Society of India, which gives it direct reach into the organised community of retina specialists and vitreoretinal surgeons across the country. Its editorial coverage spans surgical retina, medical retina, diabetic retinopathy, age-related macular degeneration, retinal detachment, vitrectomy, and related posterior segment conditions — making it the most subspecialty-focused vitreoretinal journal India currently publishes on a regular basis.

Q: How can I advertise in the World Journal of Retina and Vitreous in India?

The ad booking process begins with obtaining the current media kit from the publisher — either directly through wjorv.com or through an authorised healthcare journal advertising agency India like SmartAds — which will contain the rate card, publication schedule, and artwork specifications. Once the format, position, and issue are selected, an insertion order is prepared and submitted to the publisher along with the required advance payment or deposit. Artwork must be submitted by the ad material deadline specified for the chosen issue, in the required format — typically colour artwork in CDR format or high-resolution CMYK PDF. Working through a media buying agency simplifies the process considerably, as the agency handles the insertion order, artwork compliance review, and publisher coordination on the client's behalf.

Q: What are the advertising rates for the World Journal of Retina and Vitreous magazine?

WJRV advertising rates are not published openly on the journal website and must be requested from the publisher or obtained through a media buying agency. Based on our experience with comparable ophthalmology journal advertising India, a full page advertisement in colour works out to somewhere in the range of ₹30,000 to ₹60,000 per issue, while premium positions like the back cover ad and inside front cover typically command rates in the range of ₹60,000 to ₹1,20,000 depending on the issue and any multi-issue discount applied. These ad rates India are broadly consistent with the pricing of other specialist Indian medical journals of comparable circulation and audience quality, and they represent strong value when evaluated on a cost-per-relevant-reader basis rather than an absolute cost comparison with consumer media.

Q: What ad formats are available in the World Journal of Retina and Vitreous?

The standard ad formats available in WJRV include the full page advertisement, the half page advertisement, the back cover ad, the inside front cover, and the inside back cover. Insert options — loose inserts or bound-in cards — may also be available on request. Premium cover positions command higher rates and deliver greater frequency of exposure, while the full page advertisement is the most commonly booked format for pharmaceutical and device advertising campaigns. Digital advertising options, including banner placements on wjorv.com and eTOC sponsorships, are available alongside print placements and can be combined into a print and online advertising package for greater campaign reach.

Q: Who reads the World Journal of Retina and Vitreous in India?

The primary readership of WJRV consists of vitreoretinal surgeons, retina specialists, and posterior segment fellows across India, with significant concentration in the major ophthalmology centres in Mumbai, New Delhi, Chennai, Bangalore, Hyderabad, and other cities with established retina subspecialty practices. VRSI members form the core of the readership, supplemented by All India Ophthalmological Society members with a subspecialty interest in posterior segment disease, ophthalmology residents and fellows in training, and international readers accessing the journal digitally. The readership ophthalmology profile is highly specialised, which makes WJRV advertising particularly efficient for brands targeting the vitreoretinal specialist community.

Q: What is the print circulation and online readership of WJRV?

Precise circulation India figures for WJRV are not independently audited by the Audit Bureau of Circulations, which is standard for specialist medical journals in India. The print circulation is primarily driven by VRSI membership distribution, institutional subscriptions at medical college libraries and hospital ophthalmology departments, and individual subscriptions. The online readership through wjorv.com and digital access platforms extends the reach beyond the print circulation to international readers and practitioners who access journal content digitally. For advertisers, the relevant metric is not the raw circulation number but the proportion of the total retina specialist India community that the journal reaches — a figure that, by virtue of the VRSI association, is likely to be among the highest of any vitreoretinal journal India.

Q: What artwork specifications and material formats does WJRV require for ad submissions?

WJRV requires colour artwork in CDR format or high-resolution CMYK PDF or TIFF files, at a minimum resolution of 300 DPI at the final print size, with bleed allowances of approximately 3 to 5 millimetres. All fonts must be embedded or converted to outlines to avoid font substitution errors during prepress. A colour proof or print-ready PDF proof should accompany the artwork submission for colour verification. Pharmaceutical advertisers must ensure that the artwork includes all required prescribing information and complies with the WHO drug advertisement guidelines India and the OPPI Code, as non-compliant artwork will be rejected by the editorial team.

**Q: How do I book